MX2023005270A - Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxipirrolidin-2-carboxamida como inhibidores de vhl para el tratamiento de anemia. - Google Patents

Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxipirrolidin-2-carboxamida como inhibidores de vhl para el tratamiento de anemia.

Info

Publication number
MX2023005270A
MX2023005270A MX2023005270A MX2023005270A MX2023005270A MX 2023005270 A MX2023005270 A MX 2023005270A MX 2023005270 A MX2023005270 A MX 2023005270A MX 2023005270 A MX2023005270 A MX 2023005270A MX 2023005270 A MX2023005270 A MX 2023005270A
Authority
MX
Mexico
Prior art keywords
triazol
cyclopropyl
carboxamide
acetyl
anemia
Prior art date
Application number
MX2023005270A
Other languages
English (en)
Inventor
Hao Wu
Jakob Fuhrmann
Wayne J Fairbrother
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2023005270A publication Critical patent/MX2023005270A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a derivados de 1-(2-(4-ciclopropil-1H-1,2,3-triazol-1-il)-acetil)-4-hidroxipirro lidin-2-carboxamida y compuestos estructuralmente relacionados de fórmula (I) como inhibidores de VHL para el tratamiento de, por ejemplo, anemia (por ejemplo, anemia crónica o anemia asociada a enfermedad renal crónica, diálisis o quimioterapia contra el cáncer), isquemia, apoplejía o daño al sistema cardiovascular durante isquemia, para mejorar la cicatrización, o reducir la cicatrización patológica, o estimular la angiogénesis o arteriogénesis. Algunos ejemplos de compuestos son, por ejemplo: • 1-(2-(4-ciclopropil-1H-1,2,3-triazol-1-il)-3,3-dimetilbutanoil)- 4-hidroxipirrolidin-2-carboxamida; • 1-(2-(4-ciclopropil-1H-1,2,3- triazol-1-il)-3,3-dimetilbutanoil)-4-hidroxi-N-metilpirrolidin-2- carboxamida; • 1-(2-ciclohexil-2-(4-ciclopropil-1H-1,2,3-triazol-1 -il)acetil)-4-hidroxi-N-metilpirrolidin-2-carboxamida; • 1-(3,3-dimetil-2-(1H-1,2,3-triazol-1-il)butanoil)-4-hidroxi-N-met ilpirrolidin-2-carboxamida; • 1-(2-(4-ciclopropil-1H-1,2,3-triazol -1-il)-2-(1-metilciclohexil)acetil)-4-hidroxi-N-metilpirrolidin-2 -carboxamida; • 1-(2-(4-ciclopropil-1H-1,2,3-triazol-1-il)-2-(tetr ahidro-2H-piran-4-il)acetiI)-4-hidroxi-N-metilpirrolidin-2-carbox amida.
MX2023005270A 2020-11-11 2021-11-10 Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxipirrolidin-2-carboxamida como inhibidores de vhl para el tratamiento de anemia. MX2023005270A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112611P 2020-11-11 2020-11-11
US202063119586P 2020-11-30 2020-11-30
PCT/US2021/072338 WO2022104345A1 (en) 2020-11-11 2021-11-10 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxypyrrolidine-2-carboxa|mide derivatives as vhl inhibitors for the treatment of anemia

Publications (1)

Publication Number Publication Date
MX2023005270A true MX2023005270A (es) 2023-05-23

Family

ID=78822103

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005270A MX2023005270A (es) 2020-11-11 2021-11-10 Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxipirrolidin-2-carboxamida como inhibidores de vhl para el tratamiento de anemia.

Country Status (10)

Country Link
US (1) US20230271944A1 (es)
EP (1) EP4244219A1 (es)
JP (1) JP2023550609A (es)
KR (1) KR20230107280A (es)
AU (1) AU2021379781A1 (es)
CA (1) CA3199926A1 (es)
IL (1) IL302677A (es)
MX (1) MX2023005270A (es)
TW (1) TW202227056A (es)
WO (1) WO2022104345A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2013106646A2 (en) * 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase

Also Published As

Publication number Publication date
EP4244219A1 (en) 2023-09-20
CA3199926A1 (en) 2022-05-19
AU2021379781A1 (en) 2023-06-08
WO2022104345A1 (en) 2022-05-19
KR20230107280A (ko) 2023-07-14
JP2023550609A (ja) 2023-12-04
IL302677A (en) 2023-07-01
TW202227056A (zh) 2022-07-16
US20230271944A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
CR20220230A (es) Inhibidores de pequeñas moléculas de mutante g12c de kras
RU2413727C2 (ru) Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ
MX2023007192A (es) Inhibidores de prmt5.
CL2023001461A1 (es) Inhibidores de prmt5 novedosos
JP2013510125A5 (es)
MX2023005270A (es) Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxipirrolidin-2-carboxamida como inhibidores de vhl para el tratamiento de anemia.
NZ594068A (en) Substituted benzimidazole compounds as hepatitis c virus inhibitors
EA201000196A1 (ru) Кристаллическая форма дигидрохлорида метил((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((метоксикарбонил)амино)-3-метилбутаноил)-2-пирролидинил)-1н-имидазол-5-ил)-4-бифенилил)-1н-имидазол-2-ил)-1-пирролидинил)карбонил)-2-метилпропил)карбамата
CA2397558A1 (en) Dosing regimen
WO2010151740A4 (en) Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
CN103852528B (zh) 一种泊沙康唑的检测方法
IL175522A0 (en) Substituted triazoles as sodium channel blockers
MX2008002104A (es) Derivados de 1-acildihidropirazol.
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
MX2023005305A (es) Derivados de 1-(2-(4-ciclopropil-1h-1,2,3-triazol-1-il)acetil)-4-h idroxi-n-(bencil)pirrolidina-2-carboxamida como inhibidores de vhl para el tratamiento de la anemia y el cancer.
MX2020010437A (es) Inhibidores de axl cinasa y uso de los mismos.
CR20200643A (es) Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2
MX2022001743A (es) Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.
JP2019512515A5 (es)
IL182766A0 (en) Aqueous dispersions of optical brighteners
RU2017139771A (ru) Бициклические соединения
MX2021009142A (es) Inhibidores topicos de fosfoinositol 3-cinasas.
ZA202200660B (en) Process for the preparation of ridinilazole and crystalline forms thereof
JP2017519822A5 (es)
MX2021009206A (es) Terapias contra el cancer.